Uncovering Pandora's vase

The growing problem of new toxicities from novel anticancer agents. the case of sorafenib and sunitinib

C. Porta, C. Paglino, I. Imarisio, L. Bonomi

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

As newer, molecularly targeted, anticancer drugs are entering clinical practice, a wide array of previously unrecognised and ill defined side effects of these drugs are increasingly observed. Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis. In this review, we shall deal with these poorly recognised, but sometimes extremely distressing, toxicities; pathophysiologic mechanisms will be discussed and suggestions for treatment of each toxicity will be proposed, based on the few pieces of evidence available and, especially, on our empirical experience.

Original languageEnglish
Pages (from-to)127-134
Number of pages8
JournalClinical and Experimental Medicine
Volume7
Issue number4
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Antineoplastic Agents
Toxicity
Skin
Esophagitis
Kidney Neoplasms
Gastritis
Gastroesophageal Reflux
Exanthema
Drug-Related Side Effects and Adverse Reactions
Blood Vessels
Foot
Hand
Hypertension
Pharmaceutical Preparations
Tumors
Neoplasms
sunitinib
sorafenib

Keywords

  • Dermatitis
  • Hand-foot skin reaction
  • Hypertension
  • Sorafenib
  • Sunitinib
  • Toxicity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Clinical Biochemistry
  • Medicine(all)

Cite this

@article{d502ca652f664ad3adbf071c2de77416,
title = "Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents. the case of sorafenib and sunitinib",
abstract = "As newer, molecularly targeted, anticancer drugs are entering clinical practice, a wide array of previously unrecognised and ill defined side effects of these drugs are increasingly observed. Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis. In this review, we shall deal with these poorly recognised, but sometimes extremely distressing, toxicities; pathophysiologic mechanisms will be discussed and suggestions for treatment of each toxicity will be proposed, based on the few pieces of evidence available and, especially, on our empirical experience.",
keywords = "Dermatitis, Hand-foot skin reaction, Hypertension, Sorafenib, Sunitinib, Toxicity",
author = "C. Porta and C. Paglino and I. Imarisio and L. Bonomi",
year = "2007",
month = "7",
doi = "10.1007/s10238-007-0145-8",
language = "English",
volume = "7",
pages = "127--134",
journal = "Zeitschrift für Die Gesamte Experimentelle Medizin",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",
number = "4",

}

TY - JOUR

T1 - Uncovering Pandora's vase

T2 - The growing problem of new toxicities from novel anticancer agents. the case of sorafenib and sunitinib

AU - Porta, C.

AU - Paglino, C.

AU - Imarisio, I.

AU - Bonomi, L.

PY - 2007/7

Y1 - 2007/7

N2 - As newer, molecularly targeted, anticancer drugs are entering clinical practice, a wide array of previously unrecognised and ill defined side effects of these drugs are increasingly observed. Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis. In this review, we shall deal with these poorly recognised, but sometimes extremely distressing, toxicities; pathophysiologic mechanisms will be discussed and suggestions for treatment of each toxicity will be proposed, based on the few pieces of evidence available and, especially, on our empirical experience.

AB - As newer, molecularly targeted, anticancer drugs are entering clinical practice, a wide array of previously unrecognised and ill defined side effects of these drugs are increasingly observed. Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis. In this review, we shall deal with these poorly recognised, but sometimes extremely distressing, toxicities; pathophysiologic mechanisms will be discussed and suggestions for treatment of each toxicity will be proposed, based on the few pieces of evidence available and, especially, on our empirical experience.

KW - Dermatitis

KW - Hand-foot skin reaction

KW - Hypertension

KW - Sorafenib

KW - Sunitinib

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=38349030422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349030422&partnerID=8YFLogxK

U2 - 10.1007/s10238-007-0145-8

DO - 10.1007/s10238-007-0145-8

M3 - Article

VL - 7

SP - 127

EP - 134

JO - Zeitschrift für Die Gesamte Experimentelle Medizin

JF - Zeitschrift für Die Gesamte Experimentelle Medizin

SN - 1591-8890

IS - 4

ER -